PTC Therapeutics, Inc.
Financials
Valuation Metrics
PTC Therapeutics, Inc.'s Market Cap is $5.65B. At end of 2025 it was $6.13B. Ranked #1308 of 3,112 in US market (top 42%), #440 of 1,445 on NASDAQ (top 30%), #74 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 28%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.65B | US#1,308/3,112 Sec#74/269 |
| Revenue | $1.01B | US#1,935/3,112 Sec#53/269 |
| Net Income | $-38M | US—/3,112 Sec—/269 |
| Total Assets | $3.25B | US#1,748/3,112 Sec#42/269 |
| Net Assets | $105M | US#2,876/3,112 Sec#229/269 |
| Employees | 991 | US#1,262/3,112 Sec#33/269 |
| Value | ||
| P/B | 53.85x | US#2,932/3,112 Sec#251/269 |
| P/S | 5.60x | US#2,343/3,112 Sec#89/269 |
| EV/EBITDA | 84.70x | US#2,418/3,112 Sec#84/269 |
| FCF Yield | -1.32% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -36.58% | US#2,672/3,112 Sec#144/269 |
| ROA | -1.18% | US#2,324/3,112 Sec#81/269 |
| Op. Margin | 11.52% | US#1,502/3,112 Sec#62/269 |
| Revenue Growth | 101.55% | US#141/3,112 Sec#30/269 |
| Financial Health | ||
| Debt Ratio | 3255.48% | US#2,951/3,112 Sec#260/269 |
| Total Debt | $696M | US#1,656/3,112 Sec#52/269 |
| FCF | $-75M | US#2,530/3,112 Sec#131/269 |
| Cash | $1.05B | US#663/3,112 Sec#32/269 |
| Current Ratio | 3.39x | US#693/3,112 Sec#182/269 |
| Net Debt/EBITDA | -5.65x | US#59/3,112 Sec#2/269 |
| Performance | ||
| 1Y Return | 30.66% | US#1,194/3,112 Sec#146/269 |
| 1M Return | -18.24% | US#2,917/3,112 Sec#227/269 |
| From 52W High | -25.04% | US#1,946/3,112 Sec#139/269 |
| 1Y MDD | -27.58% | US#1,198/3,112 Sec#70/269 |
| Trading | ||
| Volume | 1,357,554 shares | US#1,208/3,112 Sec#119/269 |
| Trading Value | $92M | US#969/3,112 Sec#58/269 |
| Per Share | ||
| EPS | $8.46 | US#324/3,112 Sec#11/269 |
Company Info
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.